of the EF loop in the SH2 domain in determining binding selectivity at the third position after the phosphotyrosine.
Polyomavirus middle T antigen (MT) has provided a useful model for studying cell transformation. Analysis of MT established the connection between tyrosine phosphorylation and transformation (12) . Later, several groups (2, 6, 9) used MT to study the activation of cellular tyrosine kinases such as pp6Ocsrc in relation to their C-terminal tyrosine phosphorylation. More recently polyomavirus MT has played an important role in implicating phosphatidylinositol (PI) 3-kinase as an important enzyme in signal transduction pathways (10, 17, 18, 42) . It is now clear that PI 3-kinase associates with almost all activated tyrosine kinases (4) . Its importance has been demonstrated in systems of normal, as well as oncogenic, growth regulation. Valius and Kazlauskas (39) and Fantl and colleagues (14) , for example, implicated PI 3-kinase as a downstream mediator of the mitogenic signal of platelet-derived growth factor (PDGF).
Analysis of MT called attention to the role of tyrosine phosphorylation in redirecting PI 3-kinase (8) . The association of the p85 subunit of the enzyme with MT was shown to depend upon tyrosine phosphorylation of MT at residue 315 (8, 37) . This phosphorylation resulted in trafficking of PI 3-kinase from the cytosol to membrane fractions. The importance of this activation is clearly shown by the inability of MT mutant at residue 315 to transform cells and induce tumors (5, 16) .
The tyrosine phosphorylation site at residue 315 of MT interacts with the Src homology 2 (SH2) domains of PI 3-kinase (43) . This result is expected in view of the known role of SH2 domains in binding tyrosine-phosphorylated proteins (21, 25, 32) . Because SH2 domains are a common feature of many proteins involved in signal transduction, considerable attention has been devoted to their study. To understand the general architecture of SH2 domains, X-ray crystallography critical nature of the SH2 domain FLVR sequence, well known from previous genetic studies, could be explained by its coordination of the phosphotyrosine. Other features could also be interpreted. Consensus analysis suggested that SH2 domain recognition was strongly influenced by residues directly after the phosphotyrosine of the protein being bound (4). Songyang and colleagues (34, 35) devised a method to select for phosphopeptides that are preferentially bound by particular SH2 domains; for example, while p85 SH2 domains prefer pYMXM motifs, the GRB2 SH2 domain selected pYVNV and the Src SH2 domain selected pYEEI. Structural analysis provides a framework within which to consider these results. Waksman and colleagues compared the Src SH2 domain-YEEI peptide interaction to a two-holed socket (SH2 domain) and a twopronged plug (peptide), whereby the phosphotyrosine of the peptide would constitute one element of the binding (charged pocket) and the isoleucine would constitute the second element (hydrophobic interactions) (41) .
An important goal is to understand why SH2 domains work the way they do. While important information can be obtained by examination of consensus sequences and judicious choice of targets for mutagenesis, a random approach allows the possibility of detecting important elements perhaps unsuspected from a priori analysis. This study used random mutagenesis to determine residues critical for the recognition of MT by the N-SH2 region of p85. Intriguingly, both activating and inactivating mutations have been identified. Among them are residues apparently critical for assembling a functional SH2 domain. More interestingly, specific recognition of particular tyrosine-phosphorylated proteins, that is, residues important for the selectivity of the domain, were also uncovered. A consequence of this selectivity is that mutations affect interac- tions of the SH2 domain with MT and with the PDGF receptor (PDGFr) differently. These results fit together with the structural predictions in a satisfying way.
MATERIALS AND METHODS
Clones, viruses, and antisera. The extended pGEX 3x-GST-NSH2 construct (amino acids 321 to 470) used in the hydroxylamine mutagenesis was previously described (43) . Protein expression was tested with a rabbit polyclonal antibody (antibody 163) raised against the p85 peptide DTADGTFLVR DAST conjugated to bovine serum albumin (BSA). Human P-PDGFr, MT-, and pp60csrc-expressing baculoviruses were propagated on Sf9 cells in Grace's medium (10% fetal bovine serum). Typically, the infected cells were used 40 h postinfection. MT was immunoprecipitated with a rabbit antiserum prepared by immunization with small T antigen produced in Escherichia coli (30) or with a peptide antiserum against MT residues 280 to 302. PDGFr was immunoprecipitated with SC-OS (Santa Cruz Biotechnology).
Site-directed mutagenesis. Oligonucleotide site-directed mutagenesis was performed by the a-thionucleotide procedure (38) . The BamHI-HincII fragment of p85a (43) was cloned into M13mpl8. The degenerate oligonucleotide 5' TCAC CATGCATlT(T/G)AGTAGACG(C/A)ATCT(C/T)GTACC AAAAAGGTC 3' was used to create mutations of lysine 363 to glutamine, alanine 360 to serine, and arginine 358 to glutamine. Mutants identified by sequencing were recloned by using the BamHI-HincII fragment into pGEX2T-p85. Finally, the mutations were reconfirmed by dideoxynucleotide sequencing (33) .
Hydroxylamine mutagenesis. For the mutagenesis, we slightly modified the protocol described by Feig et al. (15) . Basically, 39.5 (2, 000 Ci/mmol). After the reaction mixtures were washed with PBS, LiCl, and water, beads containing PDGFr were frozen and the MT precipitates were boiled for 2 min in a solubilization buffer containing 0.4% sodium dodecyl sulfate (SDS), 50 mM triethanolamine-Cl (pH 7.4), 100 mM NaCl, and 2 mM 2-mercaptoethanol. After boiling, the samples were spun out, the supernatants were collected, and iodoacetamide was added to a final concentration of 10 mM. Finally, one-fourth the volume of 10% Triton X-100 was added, and MT was reimmunoprecipitated from these supernatants with protein A-Sepharose and MT antibody for 1 h on ice. The reaction mixtures were washed again, and the dry beads were frozen. On the day of the experiments, MT The colonies which showed impaired MT binding were selected and grown in LB containing ampicillin, and the plasmid DNA was purified by using the Magic Miniprep kit (Promega). DNA was then sequenced by the Sanger dideoxy method (33) for double-stranded DNA. The mutant proteins were then tested in solution. In this assay, bacterial cells containing the mutated DNA were grown, induced with 0.1 mM IPTG for 3 h at 37°C, and then collected by centrifugation. The cells were lysed by osmotic shock using a slight modification of published procedures (27) . Basically, 5 ml of bacterial cells was pelleted for 10 min at 3,000 rpm in a tabletop centrifuge. The pellet was resuspended in 100 ,ul of 50 mM Tris (pH 8.0)-20% (wt/vol) sucrose, 20 [lA of 20-mg/ml fresh lysozyme was added, and the mixture was incubated for 10 min on ice (0°C). After the incubation, 14.8 [lI of 0.5 M EDTA (pH 8.0) and 650 pAl of 50 mM Tris (pH 8.0)-7% (wt/vol) sucrose were added and mixed well, and the mixture was incubated for 2.5 min on ice. Finally, 200 RI of 5% Nonidet P-40 was added, and the solution was mixed well. After centrifugation at 12,000 rpm in a J2-21 centrifuge for 30 min at 4°C, the clear supernatant was incubated for 1 h at room temperature with glutathione-agarose beads. The beads were then washed several times with PBS and resuspended in water (1:1 [vol/vol]). Before the solution binding assay, aliquots of these beads were run on mini-SDS-polyacrylamide gels which were stained with Coomassie brilliant blue to assess the concentration of the protein. The gels were stained with a solution of Coomassie brilliant blue (0.25% [wt/vol] Coomassie brilliant blue, 10% acetic acid, 50% methanol), and then destained (7.5%, acetic acid, 5% methanol).
MT/PDGFr solution binding. Different concentrations of the fusion proteins on beads were incubated with a fixed amount of 32P-labeled MT or PDGFr for 1 h on ice. All reactions were carried out in polypropylene tubes, and the differences in bead volumes from one sample to another were corrected by the addition of glutathione-agarose, so that the resulting volumes were equal. After incubation, the beads were washed once with PBS, twice with 0.5 M LiCl, and one last time with PBS. The buffers of the last two washes contained 100 ,ug of BSA per ml, which prevented the beads from sticking to the GENETIC ANALYSIS OF A PI 3-KINASE SH2 DOMAIN 5931 tubes. The samples were then boiled in SDS sample buffer and run on an SDS-7.5% polyacrylamide gel. The gels were stained with Coomassie brilliant blue and then dried. The MT or PDGFr bound was analyzed with a Molecular Dynamics Phosphorlmager, and the amount of SH2 fusion protein in each reaction was measured by scanning on a Visage Scanner (Millipore).
Phosphopeptide library assay. The assay is described in detail elsewhere (34, 35) . The (Fig. 1B, lane 7) . The same was true for G375R (not shown). These probably could not renature successfully on the filter, thus appearing mutant in the first screen. E-403 has been suggested to be involved in calcium binding (22) (Fig. 1B, lanes 3 and 4) b Residues that are conserved within at least three subfamilies of SH2 domains according to Koch et al. (21) . The positions of the last four mutants and their degrees of conservation were not determined (ND), as these were not included in the Src structure (41) or the SH2 domain description (21) . ' Results of the MT binding assay in solution. -, .10-fold reduction in binding; +/-, denotes 4-to 10-fold reduction; +, 2-to 4-fold reduction; + +, reduction of less than 2-fold; >++ + +, binding 2.5-to 3-fold greater than the wild-type level. The four insoluble mutants (I) could not be tested. experiments were carried out as a function of increasing protein concentration. An example of the data for such an experiment is shown in Fig. 2A for the wild-type SH2 domain. The amount of fusion protein was assessed by densitometry of Coomassie brilliant blue-stained gels; the amount of MT was measured with a Molecular Dynamics Phosphorlmager. Figure  2B shows that W335R is an example of a mutant with little binding ability, while V401M is reduced somewhat more than twofold. Mutation and effects on SH2 domain specificity. SH2 domains are known to show specificity for binding tyrosinephosphorylated sequences. To establish the effects of some of these mutations on specificity, two different approaches were taken. In one set of experiments, the behavior of PDGFr was compared with that of MT. PDGFr is also known to bind to the upstream SH2 domain of p85 (13, 39 p85 binds a different PDGFr phosphotyrosine, it has been suggested that the N-SH2 domain used here binds to YVPM at 751 (19, 28) . Mutant P427L is almost as completely defective in binding PDGFr as it was in binding MT (Fig. 4) . D394N has a comparable increase in affinity for both the receptor and MT. The other up mutant, S380L, also showed a similar increase in binding for both MT and PDGFr (data not shown). Despite the similarity of the binding motifs for the two proteins, differences were observed with some mutants. Figure 4 shows that neither mutation P395S nor mutation S393F appeared to affect the binding of phosphorylated PDGF receptor as much as MT.
SH2 domains show specificity for the residues following the phosphotyrosine (4) . This specificity can be demonstrated by examination of the binding of degenerate phosphopeptides (34, 35) . In this assay, the purified SH2 domain is incubated with a library of phosphopeptides random at three positions after the phosphotyrosine. Sequencing of the bound peptides reveals enrichment of particular amino acids at the three random positions. The upstream SH2 domain of p85, a prototype used to develop the assay, has a strong preference for methionine at the third position after the phosphotyrosine, no preference at the second position, and preference for methio- C-SH2 domain, the ,C3 alanine is coordinating the tyrosine ring (31) . This may well explain the defect, but T369I may also affect gross structure like L370F. W335 is in PA. Although not apparently directly involved in interactions with phosphotyrosine, this residue is in a position where a mutation could affect other residues interacting with the phosphotyrosine. Its mutation, particularly an arginine replacement, could well perturb the interactions of the FLVR arginine at ,B5 or arginine 340 of otA with the phosphotyrosine (Fig. 6A) . Mutation of serine 339, which reduced MT binding approximately threefold, is likely to act in a similar manner. A-360 in p85 corresponds to S-177 in the Src SH2 domain, which according to Waksman et al. (41) is on the second ,B strand and constitutes an important element of the phosphotyrosine recognition. A-360 also corresponds to S-173 in the Abl SH2 domain; this residue was also shown by mutagenesis studies to be important for binding (26) . While site-directed mutagenesis of A-360 to serine did not significantly impair MT binding, mutation to valine reduced activity. S380L is a mutant that showed enhancement for binding of both MT and PDGFr. It corresponds to Src H-201, which was shown by Waksman et al. (41) to be crucial for phosphotyrosine binding, apparently because it provides hydrophobic interactions with the phosphotyrosine ring system. The same histidine (1D4) in the phospholipase C-y C-SH2 domain acts the same way (31) . If the hydrophobic character of the histidine is required for the Src SH2 domain, it is not surprising that leucine 380 in the p85 N-SH2 domain would be more favorable than serine. In the GTPase-activating protein N-SH2 domain, mutation of histidine to glutamate or lysine abolished EGFr binding (23) . Results with the Src SH2 domain point to a limitation in these sorts of simple comparisons. Mutation of H-201 to leucine reduced binding slightly rather than enhancing it (1). It is likely, and NMR studies confirm, that mutations have effects beyond individual residues, which make definitive conclusions difficult.
Mutations in the +3 pocket. Some of the most interesting mutations affect the binding pocket for the hydrophobic residue at the third position after the phosphotyrosine. MT binds the SH2 domain through its sequence at 315 pYMPM. Early predictions of specificity and binding were made by the observation that such a sequence represented a consensus (4) . The specificity of the N-SH2 domain determined from peptide binding experiments is MVIE at the first position, anything at the second position, and methionine at the third position. It is particularly striking that three mutations at residues 393, 394, and 395 came out of the mutant search. These are the three residues of the EF loop. The EF loop is part of the hydrophobic binding pocket. In Src, the EF loop moves to a more closed form when a pYEEI peptide binds (41) . S393F and P395S both reduce affinity for MT, while D394N shows enhanced binding. Binding of random peptides showed increases or decreases in preference for methionine at the +3 position that were expected based on the MT binding data. The enhanced binding of the D394N mutant can be explained since a neutral polar residue is more likely to be tolerated in the hydrophobic binding pocket than a negatively charged one. Other mutations that affect the hydrophobic binding pocket were also encountered. In the Src model, aB forms a base for the pocket. S400F on the edge of and V401M within that helix show reduced MT binding. The BG loop forms the other element. Again, S412F and L425F in that loop were defective in MT binding.
Both similarities and differences were observed when MT and PDGFr binding to mutant proteins were compared. of MT and PDGFr. On the other hand, mutations in the EF loop discriminate between MT and the receptor. PDGFr binding was less affected by mutation at 393 and 395 than MT binding, even though both proteins have pTyr-X-X-Met motifs. A likely explanation for this result is the altered affinity at the first position after the phosphotyrosine. Binding sites for p85 in PDGFr are YMDM and YVPM at tyrosines 740 and 751, compared with pYMPM for MT. The peptide sequencing experiments show some alterations in preference at the first position. In the case of P395S, for example, there is an increased preference for valine compared with methionine at the first position (Fig. 5) , so this mutant might be expected to bind much better to the pYVPM site of PDGFr than to the pYMPM site of MT. It is possible that failure of the +3 pocket to accommodate the side chain of methionine forces the peptide backbone to a distinct conformation that enhances affinity for valine at +1. An alternative possibility raised by NMR data (32a) is that some changes in the environment for additional residues besides that of the mutation could affect the +1 pocket. Settling the issue will require a better understanding of the tertiary structure of mutant and wild-type p85 N-SH2 domain. Interestingly, after this report was submitted for publication, Marengere and coworkers reported a change in the specificity in the Src SH2 domain by mutation of residue EF1 (24) . This result is generally consistent with the theme developed here, although here a stronger effect is seen with EF3.
One final point is worth noting. Point mutations made in the laboratory can give rise to SH2 domains that bind better than the naturally occurring ones. Why are these not already found in p85? It is possible that this is simply an artifact of the assay. It is possible that the wild-type structure is optimized, but for a protein with a sequence different from that of MT or PDGFr. However, there is another explanation, based on the need for regulation, that is more appealing. Tyrosine phosphorylation is known to be part of the process by which p85 is released from middle T (7). It appears that intramolecular interactions occur between tyrosine phosphorylation sites on p85 and the SH2 domains (16b) . If the affinity were too strong between the SH2 domain and the tyrosine phosphorylation sequence, then the regulation would be compromised.
